Liafensine - Denovo Biopharma
Alternative Names: BMS-820836; DB 104Latest Information Update: 28 Jan 2026
At a glance
- Originator AMRI
- Developer Bristol-Myers Squibb; Denovo Biopharma
- Class Antidepressants; Isoquinolines; Naphthalenes; Pyridazines; Small molecules; Tetrahydroisoquinolines
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Depressive disorders
- No development reported Major depressive disorder
Most Recent Events
- 28 Jan 2026 No recent reports of development identified for preclinical development in Major depressive disorder in USA
- 16 Sep 2025 Denovo Biopharma plans to file NDA for Depressive disorders (Treatment-resistant)
- 14 Aug 2025 Phase-III clinical trials in Depressive disorders (PO) prior to August 2025